Last update 21 Nov 2024

Ethoheptazine Citrate

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Ethoheptazine citrate (JAN)

Target-

Mechanism-

Therapeutic Areas

Nervous System Diseases

Active Indication

Pain

Inactive Indication-

Originator Organization-

Active Organization-

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Structure

Molecular FormulaC16H23NO2

InChIKeyWGJHHMKQBWSQIY-UHFFFAOYSA-N

CAS Registry77-15-6

View All Structures (2)

100 Clinical Results associated with Ethoheptazine Citrate

100 Translational Medicine associated with Ethoheptazine Citrate

100 Patents (Medical) associated with Ethoheptazine Citrate

Literatures (Medical) associated with Ethoheptazine Citrate

01 Feb 1987·The British journal of clinical practice

Mefenamic acid, chlormezanone-paracetamol, ethoheptazine-aspirin-meprobamate: a comparative study in acute low back pain.

Article

Author: Sweetman, B J ; Parsons, D L ; Baig, A

01 Jan 1983·Journal of Chromatography B: Biomedical Sciences and Applications

Determination of ethoheptazine in human post mortem material

Article

Author: M. Boelens ; I. Sunshine ; R.A.A. Maes ; R.H. Drost

Ethoheptazine [77-15-6] (I) was determined in the blood, liver, kidney, spleen and brain of a fatal overdose victim by gas chromatog. after extraction into Et₂O-C₆H₁₄-iso-PrOH (4:1:0.1).Pethidine-HCl was used as an internal standardThe min. detectable concentration of I in blood plasma was 1.0 μg/mL and recoveries of I from spiked samples were 85%.Total recovery of I from the other tissues was 80%.Thus, this method is adequate for studying the postmortem distribution of I in biol. material.

01 Nov 1979·The Journal of pharmacology and experimental therapeutics

Investigation of narcotics and antitussives using drug discrimination techniques.

Article

Author: Batta, S K ; Overton, D A

Rats learned drug discriminations in a shock-escape T-maze task. They were trained to turn right in the maze following injection of a drug (D) and left when no injection (N) was given. Number of training sessions before criterion performance (STC) was used to indicate degree of discriminability of the training drug. STC decreased monotonically as dosage increased, and reached a minimum of 3 to 26 with various agonists. Most agonists were not highly discriminable. Daily maintenance injections of morphine, 200 to 600 mg/kg, increased the STC of morphine, 15 mg/kg, significantly, but complete tolerance to discriminable drug actions was not observed. After rats discriminated D vs. N, they were tested with novel drugs to determine which would elicit D choices. Most morphine-like agonists substituted for one another during substitution tests; the tested agonists included alphaprodine, codeine, fentanyl, heroin, meperidine, methadone, morphine, piminodine and propoxyphene. In a few instances, one of these agonists failed to substitute for another. Naloxone and naltrexone antagonized the discriminable effects of morphine. Cyclazocine, levallorphan, naltrexone, dextromethorphan, ethoheptazine and the narcotic agonists did not substitute for one another, suggesting that six dissimilar discriminable effects were produced by these drugs.

100 Deals associated with Ethoheptazine Citrate

External Link

KEGG	Wiki	ATC	Drug Bank
D01435	Ethoheptazine Citrate	N02	DB08988

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain	-	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis